2007, Number 3
<< Back Next >>
Ann Hepatol 2007; 6 (3)
Geographical distribution of HCV genotypes in Mexico
Sánchez-Ávila JF, González E, Vázquez V, Suárez S, Uribe M
Language: English
References: 29
Page: 156-160
PDF size: 106.92 Kb.
ABSTRACT
Chronic hepatitis C (CHC) is the second cause of end-stage liver disease in our country and one of the main indications of liver transplantation. Hepatitis C virus (HCV) genotype is the principal prognostic factor and the determinant of the therapeutic scheme. In our country few data exist regarding the prevalence of HCV infection and genotype distribution in the Mexican Republic has not been determined. The aim of this study was to characterize the prevalence of the different HCV genotypes and to explore their geographical distribution.
Methods: Mexican patients with hepatitis C infection, detected throughout the country between 2003 and 2006, were included. All samples were analyzed by a central laboratory and Hepatitis C genotype was identified by Line Immuno Probe Assay in PCR positive samples (Versant
® Line Probe Assay Quest Diagnostics Nichols Institute, San Juan Capistrano CA). Data were analyzed according to the four geographical areas in Mexico.
Results: One thousand three hundred and ninety CHC patients were included. The most frequent genotype detected was genotype 1 (69%) followed by genotype 2 (21.4%) and genotype 3 (9.2%). Genotype 4 and 5 were infrequent. There was no subject infected with genotype 6. Genotype 1 and 2 exhibit very similar distribution in all geographical areas. Genotype 3 infected patients were more frequent in the North region (52%) compared with other areas: center-western (30%), center (17%), South-South east (1%) (p ‹ 0.001).
Conclusions: The most prevalent HCV genotype in Mexico is genotype 1. Geographical distribution of HCV genotypes in the four geographical areas in Mexico is not homogenous with a greater frequency of genotype 3 in the north region. This difference could be related to the global changes of risk factors for HCV infection.
REFERENCES
Instituto Nacional de Estadística Geografía e Informática. Información estadística. Porcentaje de defunciones generales por sexo y principales causas. http://www.inegi.gob.mx/est/contenidos/espanol/rutinas/ept.asp?t=mpob45&c=3222. accessed february 10, 2007.
Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdes P, Gonzalez D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52-5.
Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 41-6.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
Pellicano R, Mladenova I, Dimitrova SM, Bruno CM, Sciacca C, Rizzetto M. The epidemiology of hepatitis C virus infection. An update for clinicians. Minerva Gastroenterol Dietol 2004; 50: 1-7.
Mendez-Sanchez N, Aguilar-Ramirez JR, Reyes A, Dehesa M, Juarez A, Castaneda B, Sanchez-Avila F, et al; Grupo de Estudio, Asociación Mexicana de Hepatología. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-3.
Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: A systematic review. Intervirology 2007; 50: 1-8.
Mendez-Sanchez N, Motola-Kuba D, Zamora-Valdes D, Sanchez-Lara K, Ponciano-Rodriguez G, Uribe-Ramos MH, Vasquez-Fernandez F, et al. Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. Ann Hepatol 2006; 5: 276-80.
Benitez-Arvizu G, Cortez-Gomez R, Novelo-Garza BA, Malagon-Martinez A, Guerra-Marquez A, Alvarado-Maldonado M del C, Rodriguez-Bartolo M, et al. Prevalence of hepatitis C virus in the blood bank at Centro Médico Nacional La Raza. Rev Med Inst Mex Seguro Soc 2006; 44: 227-33.
Mendez-Sanchez N, Ponciano-Rodriguez G, Chavez-Tapia NC, Motola-Kuba D, Almeda-Valdes P, Sanchez-Lara K, Ramos MH, Uribe M. Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city. Dig Dis Sci 2005; 50: 733-7.
Rivera-Lopez MR, Zavala-Mendez C, Arenas-Esqueda A. Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors. Gac Med Mex 2004; 140(6): 657-60.
Lopez RA, Romero-Estrella S, Infante-Ramirez L, Mendez-Aquino JS, Berron-Ruiz P, Morales-Alfaro NA, Vivar R, Carrada E, Rivera-Rendon Mdel R, Sanchez-Guerrero SA. Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form. Transfusion 2004; 44: 1344-9.
Gongora-Biachi RA, Castro-Sansores CJ, Gonzalez-Martinez P, Lara-Perera DM, Garrido-Palma J, Lara-Perera V. Frequency of antibodies against the hepatitis C virus in patients with hepatic cirrhosis in Yucatan, Mexico. Salud Publica Mex 2003; 45: 346-50.
Vivas-Arceo C, Benavides SA, De Jesus Trujillo J, Panduro A, Rivas-Estilla AM. Hepatitis C virus: prevalence and routes of infection among blood donors of West Mexico. Hepatol Res 2003; 25: 115-123.
Carreto-Velez MA, Carrada-Bravo T, Martinez-Magdaleno A. Seroprevalence of HBV, HCV, and HIV among blood donors in Irapuato, Mexico. Salud Publica Mex 2003; 45: S690-3.
Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-30.
WHO. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
The Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. Clin Pharmacol 2004; 44: 20-9.
Weck K. Molecular methods of hepatitis C genotyping. Expert Rev Mol Diagn 2005; 5: 507-20.
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
Mohsen AH, Trent HCV study group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001; 48: 707-713
Soza A, Arrese M, Gonzalez R, Alvarez M, Perez RM, Cortes P, Patillo A, Riquelme A, Riquelme A. Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C. Ann Hepatol 2004; 3: 146-51.
Yamada G, Tanaka E, Miura T, Kiyosawa K, Yano M, Matsushima T, Tsubouchi H, Ishikawa K, Kohara M, Hino K, et al. Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver disease; a multi-institution analysis. J Gastroenterol Hepatol 1995; 10: 538-545.
Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3: S97-S101.
Vera de Leon L, Juarez-Navarro JA, Diaz-Gomez M, Mendez-Navarro J, Chirino-Sprung RA, Dehesa-Violante M, Casillas-Davila L, et al. Epidemiologic and situational panorama of hepatitis C in Mexico. Rev Gastroenterol Mex 2005; 70: 25-32.
Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005; 25: 18-32.
Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 405-13.
Informe de vigilancia epidemiológica de las adicciones (SISVEA) México 2002. Consejo Nacional contra las adicciones. http://www.conadic.gob.mx/interior/menu_superior/investigacion_y_estadistica/enc_nal_adicciones_2002.html accessed january 10, 2007.
Vazquez-Flores JA, Valiente-Banuet L, Marin y Lopez RA, Sanchez-Guerrero SA. Safety of the blood supply in Mexico from 1999 to 2003. Rev Invest Clin 2006; 58: 101-8.